Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 8:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 258 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ACTOS/pioglitazone Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Effect Of Modafinil And Pioglitazone On The Pharmacokinetics Of Palbociclib (PD-0332991)

NCT02222441
View directory record Official record
Conditions
Healthy
Interventions
Palbociclib alone, Palbociclib plus Modafinil, Palbociclib plus pioglitazone
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 20, 2015 · Synced Oct 17, 2026, 8:42 AM EDT
Terminated Phase 4 Interventional Results available

Thiazolidinedione Intervention With Vitamin D Evaluation

NCT00879970
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
pioglitazone, rosiglitazone, placebo, Vitamin D, Placebo
Drug · Dietary Supplement
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
1,332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
23
States / cities
Long Beach, California • Los Angeles, California • Northridge, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 17, 2026, 8:42 AM EDT
Completed Not applicable Interventional Results available

Preservation of Beta-cell Function in Type 2 Diabetes Mellitus

NCT00232583
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Metformin, Insulin, Metfomin, Pioglitazone, glyburide
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
25 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 14, 2017 · Synced Oct 17, 2026, 8:42 AM EDT
Completed Phase 4 Interventional

"TAKE TIME" Pioglitazone Reverses Defects in Mitochondrial Biogenesis in Patients With T2DM

NCT00402012
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Pioglitazone
Drug
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 18, 2015 · Synced Oct 17, 2026, 8:42 AM EDT
Completed Phase 2Phase 3 Interventional

Placebo and Active Controlled Study of Rivoglitazone in Type 2 Diabetes

NCT00143520
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Rivoglitazone, Pioglitazone, Placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 75 Years
Enrollment
441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
74
States / cities
Birmingham, Alabama • Columbiana, Alabama • Huntsville, Alabama + 71 more
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Oct 17, 2026, 8:42 AM EDT
Completed Phase 2 Interventional Results available

A Randomized, Placebo-Controlled, Double-Blind Pilot Study of Pioglitazone Hydrochloride in Severe, Refractory Asthma

NCT00994175
View directory record Official record
Conditions
Severe, Refractory Asthma, Airway Inflammation, Airflow Obstruction
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
2
States / cities
Bethesda, Maryland • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Oct 17, 2026, 8:42 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset

NCT01931566
View directory record Official record
Conditions
Mild Cognitive Impairment Due to Alzheimer's Disease
Interventions
Pioglitazone, Pioglitazone placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
65 Years to 83 Years
Enrollment
3,494 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
34
States / cities
Phoenix, Arizona • Sun City, Arizona • Long Beach, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Oct 17, 2026, 8:42 AM EDT
Completed Phase 2 Interventional Results available

Pioglitazone to Treat Fatty Liver in People With HIV Infection

NCT00441272
View directory record Official record
Conditions
HIV Infections, Hepatic Steatosis, Insulin Resistance
Interventions
Pioglitazone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 19, 2010 · Synced Oct 17, 2026, 8:42 AM EDT
Completed Phase 2 Interventional

Study In People With Type 2 Diabetes

NCT00196989
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Pioglitazone, GW677954
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
69
States / cities
Birmingham, Alabama • Northport, Alabama • Chandler, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 17, 2026, 8:42 AM EDT
Terminated Phase 4 Interventional Results available

Fatty Liver Study in Patients With Type II Diabetes

NCT02365233
View directory record Official record
Conditions
Type II Diabetes, Nonalcoholic Fatty Liver
Interventions
DPP4 inhibitor, Pioglitazone, Lantus insulin
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 17, 2026, 8:42 AM EDT
Completed Phase 4 Interventional

A Portion-controlled Diet Will Prevent Weight Gain in Diabetics Treated With ACTOS

NCT00219440
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Actos plus standard diet, Actos plus structured diet, Metformin plus standard diet
Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
35 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 25, 2016 · Synced Oct 17, 2026, 8:42 AM EDT
Terminated Phase 4 Interventional Results available

Oral Anti Diabetic Agents in the Hospital

NCT04416269
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Oral Anti-diabetes Drugs alone, Basal bolus insulin, Supplemental insulin, Continuous glucose monitoring (CGM)
Drug · Device
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 17, 2026, 8:42 AM EDT
Completed Phase 4 Interventional Results available

Effect of Pioglitazone on TIMP-3 and TACE in Type 2 Diabetes

NCT01223196
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2016 · Synced Oct 17, 2026, 8:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Characterize the Effect on the Pharmacokinetics of ASP1941 and Pioglitazone Hydrochloride When Given Together to Healthy Subjects

NCT01088919
View directory record Official record
Conditions
Healthy, Pharmacokinetics of ASP1941
Interventions
ASP1941, pioglitazone hydrochloride
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 16, 2010 · Synced Oct 17, 2026, 8:42 AM EDT
Terminated Phase 2 Interventional Results available

ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment

NCT02917629
View directory record Official record
Conditions
Oral Cavity Neoplasm, Oropharyngeal Neoplasm, Stage 0 Oral Cavity Squamous Cell Carcinoma American Joint Committee on Cancer (AJCC) v6 and v7, Stage 0 Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage I Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage I Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7
Interventions
Laboratory Biomarker Analysis, Metformide Hydrochloride/Pioglitazone Hydrochloride Extended-Release Tablet, Pharmacological Study, Placebo
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Baltimore, Maryland • Minneapolis, Minnesota • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2023 · Synced Oct 17, 2026, 8:42 AM EDT
Completed Phase 2 Interventional Results available

Dose-Ranging Study in Treatment Naive Type 2 Diabetes Mellitus(T2DM)

NCT00500331
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK189075, pioglitazone, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
14
States / cities
Mesa, Arizona • Hollywood, Florida • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Oct 17, 2026, 8:42 AM EDT
Completed Phase 4 Interventional

Pioglitazone in Hepatitis C

NCT00189163
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Pioglitazone, Placebo Oral Tablet
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 17, 2026, 8:42 AM EDT
Terminated Phase 3 Interventional Results available

Randomized, Double-blind, Active-controlled, Study of Rivoglitazone in Type 2 Diabetes Mellitus

NCT00571519
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
rivoglitazone HCl, placebo, pioglitazone HCl, pioglitazone HCl 45 mg, metformin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
18
States / cities
Huntsville, Alabama • San Diego, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Oct 17, 2026, 8:42 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Optimizing Body Composition for Function in Older Adults

NCT00315146
View directory record Official record
Conditions
Obesity, Overweight With Indications for Weight Loss
Interventions
Pioglitazone, Resistance exercise training to maximize muscle power, Hypocaloric diet, Placebo
Drug · Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
65 Years to 79 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Oct 17, 2026, 8:42 AM EDT
Completed Phase 3 Interventional Results available

The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)

NCT01106690
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, Canagliflozin, Sitagliptin, Metformin, Pioglitazone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
41
States / cities
Anniston, Alabama • Phoenix, Arizona • Tucson, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2013 · Synced Oct 17, 2026, 8:42 AM EDT
Completed Phase 1 Interventional

Study of Pioglitazone in Sporadic Inclusion Body Myositis

NCT03440034
View directory record Official record
Conditions
Myositis, Inclusion Body Myositis, Muscular Diseases, Musculoskeletal Disease, Neuromuscular Diseases, Nervous System Diseases
Interventions
Pioglitazone
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Oct 17, 2026, 8:42 AM EDT
Completed Phase 2 Interventional

Pioglitazone as an Adjunct to Cognitive-Behavioral Therapy for Cocaine Relapse Prevention

NCT04843046
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
Cognitive Behavioral Therapy (CBT), Pioglitazone, Placebo
Behavioral · Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 17, 2026, 8:42 AM EDT
Recruiting Phase 2 Interventional

Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis/Acute Pancreatitis Associated Diabetes Mellitus

NCT06729996
View directory record Official record
Conditions
Pancreatitis, Chronic, Pancreatitis, Acute, Diabetes Mellitus
Interventions
Pioglitazone (PIO), Empagliflozin (EMPA)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Rochester, Minnesota • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 17, 2026, 8:42 AM EDT
Completed No phase listed Observational

Effect of Pioglitazone on Mitochondrial Function in Muscle and Adipose Tissue in Humans

NCT01165190
View directory record Official record
Conditions
Type II Diabetes Mellitus
Interventions
pioglitazone
Other
Lead sponsor
Arizona State University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Oct 17, 2026, 8:42 AM EDT